Flowcytometry in myelodysplastic syndromes: towards a new paradigm in diagnosis and prognostication?

[1]  K. Metze,et al.  The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes. , 2008, Leukemia research.

[2]  A. Órfão,et al.  Flow cytometry in myelodysplastic syndromes: report from a working conference. , 2008, Leukemia research.

[3]  J. Bennett,et al.  Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. , 2007, Leukemia research.

[4]  T. Haferlach,et al.  Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. , 2007, Leukemia research.

[5]  G. Ossenkoppele,et al.  P086 Flow cytometry in myelodysplastic syndromes: a new tool in the classification and prognostification of low/int-I risk MDS , 2007 .

[6]  H. Tamura,et al.  P089 Biological significance of CD7-positive blasts in myelodysplastic syndromes , 2007 .

[7]  G. Ossenkoppele,et al.  P093 Changes in the flowcytometric dysplasia score during treatment with erythropoietin/G-CSF reflect responses in low/int-I risk myelodysplastic syndromes , 2007 .

[8]  A. Hagemeijer,et al.  A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification , 2007, Leukemia.

[9]  K. Metze,et al.  Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders. , 2007, Leukemia research.

[10]  Hong Chang,et al.  CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype. , 2007, Leukemia research.

[11]  M. Minden,et al.  Myelodysplastic syndromes: the complexity of stem-cell diseases , 2007, Nature Reviews Cancer.

[12]  M. Tomonaga,et al.  Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification , 2007, Leukemia.

[13]  D. Subirá,et al.  Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome. , 2006, Leukemia research.

[14]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Deeg,et al.  Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. , 2004, Leukemia research.

[16]  V. V. D. van der Velden,et al.  Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age‐related changes and disease‐induced shifts , 2004, Cytometry. Part B, Clinical cytometry.

[17]  H. Deeg,et al.  Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. , 2003, Blood.

[18]  M. Mori,et al.  Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. , 2002, Blood.